Precision Immunotherapy™
investors-relations
Home/Investor Relations/Press Releases
Investor Relations

Quick Links

Email Alerts

Email Address *
Mailing Lists *




 
Enter the code shown above.

Press Releases

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
12/01/2022 PharmaFrontiers Appoints Mathilda Mandel to Clinical Advisory Board
11/15/2005 PharmaFrontiers Shareholders Approve Increase in Authorized Shares at Special Meeting
11/15/2005 PharmaFrontiers Reports Third Quarter 2005 Financial Results; Provides Update on Research & Development Activities
11/09/2022 PharmaFrontiers Corp. Selects MDB Capital Group as Financial Advisor
11/08/2022 PharmaFrontiers Corp Elects Brooks Boveroux as Chairman; To Assume Primary Responsibility for Finance
11/02/2022 PharmaFrontiers Corp. to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare Conference
11/01/2022 PharmaFrontiers Corp. Reconstitutes Its Audit Committee
10/31/2005 PharmaFrontiers Tovaxin(TM) Phase IIb Multiple Sclerosis Clinical Trial Protocol Accepted by FDA
10/26/2005 PharmaFrontiers Corp. Elects Interim Chairman
10/25/2005 PharmaFrontiers Corp. to Present at the PIPEs Conference 2005
10/18/2005 PharmaFrontiers Corp. Names Brooks Boveroux to Board of Directors
10/17/2005 PharmaFrontiers Corp. to Present at the 2005 BIO Emerging Company Investor Forum
10/03/2022 PharmaFrontiers Presents Positive Tovaxin(TM) Research at International Multiple Sclerosis Meeting
09/22/2005 PharmaFrontiers Cancels Presentation Due to Hurricane Rita
09/21/2005 PharmaFrontiers to Present at Sanders Morris Harris Growth Conference
09/13/2005 PharmaFrontiers to Present at ValueRich Small Cap Financial Exposition
08/16/2005 PharmaFrontiers Reports Second Quarter 2005 Financial Results; Provides Research Update
08/10/2021 PharmaFrontiers to Present Tovaxin(TM) Research at International Multiple Sclerosis Meeting
07/27/2005 PharmaFrontiers Plans to Ask SEC for Accelerated Effective Date
06/20/2005 PharmaFrontiers Completes $5.08 MM Financing
06/08/2022 PharmaFrontiers Presented Preliminary Tovaxin Clinical Plans at Multiple Sclerosis Centers Meeting
06/03/2022 PharmaFrontiers Announces Positive Interim Results of Two Phase I/II Clinical Trials for Multiple Sclerosis
05/17/2005 PharmaFrontiers Adds Three Members to Its Scientific Advisory Board
05/03/2022 PharmaFrontiers Selects INC Research as Development Partner for its Novel Multiple Sclerosis Therapy
04/26/2005 PharmaFrontiers Announces Dr. Eliezer Huberman to Chair Scientific Advisory Board
04/15/2005 PharmaFrontiers Provides Update, Financial Results
© 2013 Opexa Therapeutics, Inc. All Rights Reserved.
Powered By Q4 Web Systems 4.1.3.41